Literature DB >> 6490203

Tumorigenicity of human lymphoblastoid cell lines, acquired during in vitro culture and associated with chromosome gains.

J E Morten, J H Hay, C M Steel, M E Foster, C L De Angelis, A Busuttil.   

Abstract

Tumorigenicity of human lymphoma and lymphoblastoid B-cell lines was assessed by their ability to form growing and transplantable masses on subcutaneous inoculation into neonatally thymectomized, Ara-C-protected, total-body-irradiated mice. By these criteria, 12 lines of known malignant origin were tumorigenic, 11 lymphoblastoid lines, tested after less than one year of in vitro growth, were non-tumorigenic and 8/18 long-established lymphoblastoid lines produced transplantable tumours. All of the long-established lines had acquired karyotypic changes on prolonged culture, the predominant characteristic being a gain of whole chromosomes or of major chromosome segments. None showed the classical 8:14 translocation associated with Burkitt's lymphoma. Comparisons with nontumorigenic precursors (recovered from liquid nitrogen storage) and with other non-tumorigenic but chromosomally abnormal, lymphoblastoid lines suggest that imbalance of the dosage of genes carried on chromosomes 7,8 and 9 may be important in determining the tumorigenic phenotype.

Entities:  

Mesh:

Year:  1984        PMID: 6490203     DOI: 10.1002/ijc.2910340406

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  2 in total

1.  Molecular characterization of novel reciprocal translocation t(6;14) in an Epstein-Barr virus-transformed B cell precursor.

Authors:  M Otsu; S Katamine; M Uno; M Yamaki; Y Ono; G Klein; M S Sasaki; Y Yaoita; T Honjo
Journal:  Mol Cell Biol       Date:  1987-02       Impact factor: 4.272

2.  Gene expression in oestrogen-dependent human breast cancer xenograft tumours.

Authors:  A M Thompson; C M Steel; M E Foster; D Kerr; D Paterson; D Deane; R A Hawkins; D C Carter; H J Evans
Journal:  Br J Cancer       Date:  1990-07       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.